CXCR4/CXCL12 axis inhibition has been demonstrated to revert tolerogenic polarization of tumor microenvironment (42) and to restore sensitivity to CTLA-4 and PD-1 ICIs (23, 43), overall representing a novel and effective way to counteract ICIs resistance. Here, CXCL12 is linked to neoplasm.